Artiva (ARTV) CMO Subhashis Banerjee Receives 115,000 RSUs

What Happened

• Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics (ARTV), received equity awards on September 9, 2026: 30,000 shares reported as an award and 85,000 shares reported as a derivative award (total 115,000). Both were recorded at a $0.00 grant price in the Form 4 filing. These are awards, not open‑market purchases or sales.

Key Details

• Transaction date: 2026-09-09; Form 4 filed 2026-09-11 (timely filing).
• Reported amounts: 30,000 shares (award) and 85,000 derivative shares (award); total = 115,000.
• Reported grant price: $0.00 (award/grant).
• Footnote F1: Awards represent restricted stock units (RSUs) granted under the Issuer’s 2024 Equity Incentive Plan.
• Footnote F2: Vesting begins September 8, 2026 — 1/48th of the shares subject to the award vest in equal monthly installments over four years (i.e., typical four‑year monthly vesting schedule).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context

• These are equity awards (RSUs/derivative awards). Derivative RSUs represent the right to receive shares upon vesting rather than immediately tradeable shares — they vest over time per the footnote schedule. Awards are routine compensation/retention tools and do not by themselves indicate insider buying or selling intent.